Home / Health / New Drug Offers Hope for Stubborn Head and Neck Cancers
New Drug Offers Hope for Stubborn Head and Neck Cancers
16 Jun
Summary
- Amivantamab shows promise in treating advanced head and neck cancers.
- 43 out of 102 patients saw tumor reduction; 15 had no detectable cancer.
- The drug is administered as a quick injection, unlike lengthy IV treatments.
A drug currently utilized for certain lung cancers is exhibiting encouraging results in patients battling head and neck cancers that have ceased responding to conventional treatments. The study focused on amivantamab, administered as a swift subcutaneous injection, in 102 individuals whose HPV-negative, recurrent, or metastatic head and neck cancers had progressed after prior therapies.
Impressive outcomes were observed, with tumor reduction noted in 43 participants. Notably, scans revealed no detectable cancer in 15 patients. This targeted treatment, which can be administered in minutes, offers a stark contrast to prolonged IV infusions, potentially improving patient convenience.
Researchers are now planning larger trials to further evaluate amivantamab's efficacy, including its potential when combined with other drugs. These studies aim to confirm whether the drug can replicate its promising response rate of over 40% in a heavily pre-treated patient population, offering a new therapeutic avenue where options are scarce.
